Finerenone and Quality of Life Assessed Using the EuroQol 5-Dimension Questionnaire Level Sum Score in Patients With HFmrEF or HFpEF
Open Access
- 11 October 2025
- journal article
- Published by Elsevier in JACC: Heart Failure
- Vol. 14 (2) , 102705
Abstract
No abstract availableKeywords
Funding Information
- Bayer Pharma AG
This publication has 4 references indexed in Scilit:
- EuroQol 5-Dimension Questionnaire in Heart Failure With Reduced, Mildly Reduced, and Preserved Ejection FractionJACC: Heart Failure, 2025
- Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection FractionNew England Journal of Medicine, 2024
- Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEFJACC, 2024
- Impact of Comorbidities on Health Status Measured Using the Kansas City Cardiomyopathy Questionnaire in Patients with Heart Failure with Reduced and Preserved Ejection FractionEuropean Journal of Heart Failure, 2023